Company intelligence
Leukocare AG
Experts in Sterile Drug Product Formulation Services
About Leukocare AG
For over 20 years, Leukocare has been trusted by pharmaceutical companies, mid-sized biotech firms, and innovative biotechs for our Quality by Design-driven approach to formulation development. Our proven track record includes advancing companies into clinics, filing BLAs, and enabling patent potential, demonstrating our commitment to the successful development of cutting-edge therapies. Our strength lies in combining strong formulation expertise with data science and statistical approaches, ensuring a systematic, evidence-driven path forward. With extensive experience in both liquid and lyophilized formulation development for proteins, monoclonal antibodies (mAbs), viral vectors, and viruses, we are equipped to tackle the most complex challenges combining 100+ regulatory approved excipients. However, our greatest asset is our adaptability. We remain agile, responding quickly to changes in the regulatory landscape and evolving client needs. By combining scientific expertise with a deep understanding of regulatory requirements and the latest industry advancements, we ensure that our clients are always a step ahead. Typical projects include: • Molecular Modeling and Benchmarking • Pre-Formulation • QbD Formulation Development and Optimization • Process Development and Transfer • IP Support We believe that a great formulation is not just about scientific knowledge; it’s about relevant data, an in-depth understanding of regulatory and industry standards, and the ability to adapt quickly to the changing landscape of drug development. Let’s connect to explore how we can help advance your drug product developments. You can reach out by: • Messaging us on LinkedIn to start a conversation. • Visiting our website to learn more about our services and get in touch with our team. • Emailing us directly at info@leukocare.com for personalized support.
Verified activity
Signals from Leukocare AG
6 published signals
Presence & Recognition
Leukocare AG employee Dr. Estefania Vidal will be speaking at DDF Boston on the topic of predictive approaches in formulation and CMC.
Reported by Leukocare AG
Presence & Recognition
Leukocare AG is hosting a roundtable meeting at DDF in Boston on September 14–15.
Reported by Ulrike Konrad
Presence & Recognition
Leukocare AG participated in the Antibody CMC Development Xchange in San Francisco, where a roundtable explored molecular properties and computational approaches for antibody CMC development.
Reported by Leukocare AG
Presence & Recognition
Leukocare AG hosted a roundtable titled From Data to Decisions: Computational Strategies for De-Risking Drug Product Development at HubXchange in San Francisco.
Reported by Ulrike Konrad
Presence & Recognition
Leukocare AG employee Ulrike Konrad attended the antibody CMC hubXchange event where she joined a roundtable discussion on early developability and AI from Tatjana Petojevic from Rondo.
Reported by Ulrike Konrad
Presence & Recognition
Leukocare AG is attending the DDF Summit in Boston to discuss drug product development and support needs.
Reported by Michael Scholl